Related Experiment Video
Updated: May 23, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling
Shi-Lin Tang1, Wu-Jun Chen, Kai Yin
1Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Life Science Research Center, University of South China, Hengyang, Hunan 421001, China.
Insights
Pregnancy-associated plasma protein-A (PAPP-A) reduces cholesterol efflux by down-regulating LXRα and key cholesterol transporters (ABCA1, ABCG1, SR-B1) via the IGF-1/PI3-K/Akt pathway, contributing to atherosclerosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Pregnancy-associated plasma protein-A (PAPP-A) influences atherosclerosis by regulating insulin-like growth factor-1 (IGF-1).
- IGF-1 signaling, via PI3-K/Akt, affects cholesterol efflux and nitric oxide formation.
- The PI3-K/Akt pathway can decrease cholesterol efflux by reducing ABCA1 and SR-B1 expression.
Purpose of the Study:
- To investigate PAPP-A's role in regulating liver X receptor alpha (LXRα) and cholesterol transporter expression (ABCA1, ABCG1, SR-B1).
- To determine if the IGF-1-mediated signaling pathway (IGF/PI3-K/Akt) is involved in PAPP-A's effects.
- To elucidate the mechanism by which PAPP-A contributes to the pathogenesis of atherosclerosis.
Main Methods:
- Dose- and time-dependent experiments assessing PAPP-A's effect on ABCA1, ABCG1, and SR-B1 expression at transcriptional and translational levels.
- Measurement of cellular cholesterol content and cholesterol efflux following PAPP-A treatment.
- Investigation of LXRα regulation and the involvement of the IGF-1/PI3-K/Akt pathway using specific inhibitors and siRNA.
- Analysis of PAPP-A's impact on the MAPK cascade.
Main Results:
- PAPP-A significantly decreased ABCA1, ABCG1, and SR-B1 expression in a dose- and time-dependent manner.
- PAPP-A treatment increased cellular cholesterol content and decreased cholesterol efflux.
- PAPP-A down-regulated LXRα expression, which was partially rescued by LXRα agonist activation.
- The IGF-1/PI3-K/Akt pathway, but not the MAPK cascade, was involved in PAPP-A-induced downregulation of LXRα, ABCA1, ABCG1, and SR-B1.
Conclusions:
- PAPP-A down-regulates LXRα expression through the IGF-1/PI3-K/Akt signaling pathway.
- This down-regulation leads to decreased expression of ABCA1, ABCG1, and SR-B1, impairing cholesterol efflux in macrophage-derived foam cells.
- The study elucidates a key mechanism for PAPP-A's contribution to atherosclerosis pathogenesis.
Abstract:
Pregnancy-associated plasma protein-A (PAPP-A) has been involved in the atherosclerotic process through regulation of local expression of IGF-1 that mediates the activation of the phosphatidylinositol-3 (PI3-K) and Akt kinase (Akt) signaling cascades which lead to constitutive nitric oxide formation, with its attending vasodilator, antiplatelet and insulin-sensitizing actions. In addition, IGF-1 may decreased cholesterol efflux through reductions of expression in ABCA1 and SR-B1 by the PI3-K/Akt signaling pathway. In the current study, we examined whether PAPP-A was involved in LXRα regulation and in expression of ABCA1, ABCG1 or SR-B1 through the IGF-I-mediated signaling pathway (IGF/PI3-K/Akt). Results showed that PAPP-A significantly decreased expression of ABCA1, ABCG1 and SR-BI at both transcriptional and translational levels in a dose-dependent and time-dependent manner. Cellular cholesterol content was increased while cholesterol efflux was decreased by PAPP-A treatment. Moreover, LXRα which can regulate the expression of ABCA1, ABCG1 and SR-B1, was also down-regulated by PAPP-A treatment. LXRα-specific activation by LXRα agonist almost rescued the down-regulation of ABCA1, ABCG1 and SR-B1 expression by PAPP-A. In addition, PAPP-A can induce the IGF-1/PI3-K/Akt pathway in macrophages. Furthermore, our results indicate that the decreased levels observed in LXRα, ABCA1, ABCG1 and SR-B1 mRNA and protein levels upon treating cells with PAPP-A were strongly impaired with the PI3-K inhibitors or IGF-1R siRNA while the MAPK cascade inhibitor did not execute this effect, indicating that the process of ABCA1, ABCG1 and SR-BI degradation by PAPP-A involves the IGF-1/PI3-K/Akt pathway. In conclusion, PAPP-A may first down-regulate expression of LXRα through the IGF-1/PI3-K/Akt signaling pathway and then decrease expression of ABCA1, ABCG1, SR-B1 and cholesterol efflux in THP-1 macrophage-derived foam cells. Therefore, our study provided one of the mechanisms for understanding the critical effect of PAPP-A in pathogenesis of atherosclerosis.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Two...
Regulation of Nuclear Protein Sorting
TGF - β Signaling Pathway
Cell Specific Gene Expression
Negative Regulator Molecules
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

